Biosimilar Market

A product is termed as biosimilar product, if it is a biological product with similar characteristics as that of a reference biological product, which possesses approval from agencies such as FDA. There would not be any major clinical difference in effectiveness and safety as that of reference product. Biosimilar products are made of complex molecules with high molecular weight produced through genetic engineering in living cells. Biologics drugs are costlier than respective chemical drugs. Biosimilar drugs can save around 30 to 40 % in terms of price relative to the respective biologics drugs. Biosimilars are useful for the treatment of illnesses such as anemia, autoimmune diseases, cancer, diabetes, growth hormone deficiencies, hematological diseases, kidney failure, rheumatoid arthritis and others. For the manufacturing of biosimilars, manufacturers have to develop environments that are ideal for the living cells, which remain sensitive to environmental conditions. Moreover, they need to develop distinctive process to entice the living cells for producing similar outcome to a prevalent biological treatment. The substitution of biological drugs with biosimilar drugs can save lot of money for public health care sector and patients. The regulatory authorities in developed nations are promoting biosimilar products.

Biosimilar Market contains market size and forecasts of Biosimilar in global, including the following market information:

• Global Biosimilar Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Biosimilar Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Biosimilar companies in 2021 (%)
• The global Biosimilar market was valued at 8650.9 million in 2021 and is projected to reach US$ 22110 million by 2028, at a CAGR of 14.3% during the forecast period.
• The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
• Human Growth Hormones Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Biosimilar include Allergan plc, BIOCAD, Biocon, BioXpress Therapeutics, Boehringer Ingelheim, Celltrion, Coherus BioSciences, Dr. Reddy?s Laboratories and Genor BioPharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Biosimilar manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Biosimilar Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Biosimilar Market Segment Percentages, by Type, 2021 (%)

• Human Growth Hormones
• Monoclonal Antibodies
• Insulin
• Peptides
• Erythropoietin
• Others

Global Biosimilar Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Biosimilar Market Segment Percentages, by Application, 2021 (%)

• Oncology
• Chronic and Autoimmune Diseases
• Growth Hormone Deficiency
• Infectious Diseases
• Others

Global Biosimilar Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Biosimilar Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Biosimilar revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Biosimilar revenues share in global market, 2021 (%)
• Key companies Biosimilar sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Biosimilar sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Allergan plc
• BIOCAD
• Biocon
• BioXpress Therapeutics
• Boehringer Ingelheim
• Celltrion
• Coherus BioSciences
• Dr. Reddy?s Laboratories
• Genor BioPharma
• Intas Pharmaceuticals Limited
• Novartis
• Pfizer